Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 5-month progress in treating hair loss using HIMs topical finasteride and minoxidil, micro-needling with a 1.5mm needle, and RU-58841. The post includes progress pictures showing improvement from a NW7 hair loss stage.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.

A product called "PP405 Hair Follicle Serum" is being sold on Shopee, claiming to cure baldness without clinical trials or FDA approval, but users are skeptical and refer to it as "snake oil." Some users discuss testing the product's contents, while others share their experiences with hair loss treatments like finasteride.

The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

A 57-year-old man uses a hair system, not a hair transplant, and likely had cosmetic procedures. Discussions include the effectiveness of hair systems and finasteride side effects.

A 21-year-old shared a 7-month update on using 1mg finasteride and minoxidil for hair loss, reporting positive results with no side effects except watery semen. The user initially stopped minoxidil due to inconvenience but resumed it after shedding, and is satisfied with the progress despite some thinning at the crown.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Store finasteride powder in a cool, dry place. RU58841 needs to be stored in the freezer.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.